A highly reliable partner for GMP radiopharmaceuticals
Global Morpho Pharma SAS is a French company created early 2018 that aims at developing, distributing and selling radionuclides and radiopharmaceuticals under Good Manufacturing Practice (GMP) quality for the benefit of the patients and the expanding nuclear medicine industry. Global Morpho Pharma intends to become one of the major suppliers of pharmaceutical grade doses of radiolabeled compounds for the pharmaceutical industry. The abbreviated name of the company, GMP stands as well as for Good Manufacturing Practices and points clearly to its major aims: Quality, Reliability, Sustainability.
The Blue Morpho (Morpho menelaus) is not only one of the largest butterflies, but a symbol of beauty, perfection and freedom and its iridescent metallic blue wings link directly with the only visible way to recognize radioactivity, namely the blue color of the Cherenkov Effect.
Global Morpho Pharma believes in the important short term growth of the radiotheranostic market at a worldwide level. The company selected a few radionuclides of interest for which existing sources have not yet guaranteed worldwide supply when radiolabeled drugs addressing larger indications will reach the market. There is largely room for several players active in this field, but Global Morpho Pharma took in account that major customers in this field (pharmaceutical companies as new comers) will always need access to at least two totally independent suppliers for their final product. Global Morpho Pharma is presently building a network of centers covering the entire supply chain, from the original target to the pharmaceutical grade radionuclide for human use, eventually to the final ready-to-use drug. This network includes for each step backup solutions in both the US and EU to avoid rupture of supply in case of maintenance or temporary shutdowns.
An outstanding founding team
Six experts of the nuclear medicine field came together with a common vision about the future of radiotherapeutics and radiotheranostics. With its cumulated century experience in the area this group identified the needs for the pharmaceutical industry and anticipated the very fast growth of the this modality. Ahead of developing a new drug it is even more important to guarantee access to the larger amounts of raw material needed to produce such drugs. Success of this industry is intimately linked with manufacturing quality, product availability and distribution reliability. The radionuclide and radiopharmaceutical production is one of the most complex and regulated industry in the world, but this industry is now mature. When specialists from the radiopharmaceutical industry, nuclear equipment manufacturing, business development, legal and financial, and well-known locally implanted suppliers join to create a new company in their own expertise, it can only lead to an outstanding, very reactive and success-driven team. Their extensive network allowed to select the best team members for implementing the concept and running the company for the benefit of patients.